– Reuters Citing Filing
Related Posts
Why Is AstraZeneca Stock Trading Lower On Tuesday?
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.
Guggenheim Maintains Buy on Phreesia, Raises Price Target to $35
Guggenheim analyst Jack Wallace maintains Phreesia (NYSE:PHR) with a Buy and raises the price target from $30 to $35.
KB Home’s Q2 Earnings Awaited As Options Traders Bet On Potential 10% Stock Jump
KB Home (NYSE: KBH) is expected to report results for its second quarter ended May 31, 2023, after the closing bell on June 21, 2023.